PL1622648T3 - Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania - Google Patents

Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania

Info

Publication number
PL1622648T3
PL1622648T3 PL04749425T PL04749425T PL1622648T3 PL 1622648 T3 PL1622648 T3 PL 1622648T3 PL 04749425 T PL04749425 T PL 04749425T PL 04749425 T PL04749425 T PL 04749425T PL 1622648 T3 PL1622648 T3 PL 1622648T3
Authority
PL
Poland
Prior art keywords
human
protein
tumor growth
cancer
apoptosis
Prior art date
Application number
PL04749425T
Other languages
English (en)
Inventor
Rong Xiang
He Zhou
Ralph A Reisfeld
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PL1622648T3 publication Critical patent/PL1622648T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PL04749425T 2003-03-24 2004-03-24 Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania PL1622648T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45700903P 2003-03-24 2003-03-24
EP04749425A EP1622648B1 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof
PCT/US2004/008932 WO2004099389A2 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof

Publications (1)

Publication Number Publication Date
PL1622648T3 true PL1622648T3 (pl) 2010-11-30

Family

ID=33434911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04749425T PL1622648T3 (pl) 2003-03-24 2004-03-24 Szczepionki DNA przeciwko wzrostowi nowotworów i sposoby ich stosowania

Country Status (18)

Country Link
US (2) US8716254B2 (pl)
EP (1) EP1622648B1 (pl)
JP (1) JP4616827B2 (pl)
KR (1) KR101199789B1 (pl)
CN (1) CN1791433B (pl)
AT (1) ATE472339T1 (pl)
AU (1) AU2004236636B2 (pl)
BR (1) BRPI0408774A (pl)
CA (1) CA2519953C (pl)
DE (1) DE602004027902D1 (pl)
DK (1) DK1622648T3 (pl)
ES (1) ES2345200T3 (pl)
MX (1) MXPA05010255A (pl)
PL (1) PL1622648T3 (pl)
PT (1) PT1622648E (pl)
RU (1) RU2343195C2 (pl)
WO (1) WO2004099389A2 (pl)
ZA (1) ZA200508579B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR100790377B1 (ko) * 2006-02-15 2008-01-02 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주를 함유하는항바이러스용 조성물
CA2657217A1 (en) * 2006-06-21 2007-12-27 The Scripps Research Institute Dna composition against tumor stromal antigen fap and methods of use thereof
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CA2670790A1 (en) * 2006-11-28 2008-06-05 Ghc Research Development Corporation Polypeptides comprising fas activation and nkg2d-ligand domains
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US20110027303A1 (en) 2008-03-31 2011-02-03 Bioimmulance Co., Ltd. Partial peptide of survivin presented on mhc class ii molecule and use therof
US9309493B2 (en) * 2009-03-27 2016-04-12 Eidgenoessische Technische Hochschule Zurich Salmonella enterica presenting C. jejuni N-glycan or derivatives thereof
MX2012001999A (es) * 2009-08-17 2012-02-29 Univ California Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
CN102210862B (zh) * 2011-06-01 2013-06-12 中国人民解放军南京军区福州总医院 基于Livin的免疫刺激复合物及其制备方法和应用
CN113684185A (zh) * 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
KR20230062674A (ko) * 2013-03-15 2023-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 암 백신 및 이를 이용한 치료 방법
EP2981284A1 (en) * 2013-04-05 2016-02-10 Kyushu University National University Corporation Anti-tumor dna vaccine
WO2015001082A1 (en) * 2013-07-05 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
AU2015229009B2 (en) * 2014-03-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
WO2016033532A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of California Vaccine for livestock production systems
US10414810B2 (en) 2015-05-07 2019-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Double mutant survivin vaccine
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
RU2020124191A (ru) 2015-10-01 2020-08-27 Потенза Терапевтикс, Инк. Анти-tigit антиген-связывающие белки и способы их применения
CN110691844B (zh) * 2017-02-07 2023-09-08 新加坡科技研究局 从多能干细胞产生模拟的先天免疫细胞的方法和试剂盒
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
RU2770490C1 (ru) * 2021-07-14 2022-04-18 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" Рекомбинантная плазмидная ДНК pET19b-Surv-OL, обеспечивающая синтез гибридного белка сурвивин-обелин (Surv-OL) и гибридный белок, связываемый анти-сурвивин антителами и обладающий биолюминесцентной активностью
CN116077534A (zh) * 2023-01-31 2023-05-09 大连工业大学 一种凝结芽孢杆菌的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
ATE414149T1 (de) * 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
AU737717B2 (en) * 1997-08-13 2001-08-30 Uab Research Foundation, The Vaccination by topical application of genetic vectors
WO1999031241A1 (en) * 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
AU4990999A (en) * 1998-07-14 2000-02-07 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
AU765160B2 (en) * 1998-12-18 2003-09-11 Symrise Gmbh & Co. Kg Encapsulated flavour and/or fragrance preparations
WO2002002622A2 (en) * 2000-06-29 2002-01-10 The Salk Institute For Biological Studies Crystal structure of survivin
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
EP1507540A4 (en) * 2001-10-10 2006-12-06 Centocor Inc NUCLEIC ACID VACCINES USING NUCLEIC ACIDS ENCODING A TUMOR ANTIGEN AND A NUCLEIC ACID ENCODING A CYTOKINE ADJUVANT
EP2301573A1 (en) * 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
AU2003300680A1 (en) * 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

Also Published As

Publication number Publication date
RU2005132578A (ru) 2006-05-10
AU2004236636B2 (en) 2010-02-04
WO2004099389A2 (en) 2004-11-18
US8716254B2 (en) 2014-05-06
KR20050121694A (ko) 2005-12-27
EP1622648A4 (en) 2007-02-14
AU2004236636A1 (en) 2004-11-18
BRPI0408774A (pt) 2006-03-28
US20140322249A1 (en) 2014-10-30
KR101199789B1 (ko) 2012-11-09
CA2519953A1 (en) 2004-11-18
CN1791433A (zh) 2006-06-21
EP1622648B1 (en) 2010-06-30
JP4616827B2 (ja) 2011-01-19
PT1622648E (pt) 2010-08-31
EP1622648A2 (en) 2006-02-08
JP2006523217A (ja) 2006-10-12
DE602004027902D1 (de) 2010-08-12
ATE472339T1 (de) 2010-07-15
ES2345200T3 (es) 2010-09-17
CA2519953C (en) 2016-01-05
DK1622648T3 (da) 2010-09-06
US9655815B2 (en) 2017-05-23
US20040192631A1 (en) 2004-09-30
RU2343195C2 (ru) 2009-01-10
WO2004099389A3 (en) 2005-09-29
CN1791433B (zh) 2010-05-26
ZA200508579B (en) 2007-04-25
MXPA05010255A (es) 2005-12-14

Similar Documents

Publication Publication Date Title
MXPA05010255A (es) Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Krieg Development of TLR9 agonists for cancer therapy
Li et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Van Lint et al. mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
Casares et al. Immunization with a tumor‐associated CTL epitope plus a tumor‐related or unrelated Th1 helper peptide elicits protective CTL immunity
WO1998016238A3 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
McLaughlin et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2
Chiang et al. In vivo cancer vaccination: Which dendritic cells to target and how?
DE69533334D1 (de) Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff
Chakravarty et al. Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy
AU2005314271B2 (en) Alpha thymosin peptides as cancer vaccine adjuvants
Macedo et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Tewari et al. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
CN111375054A (zh) 一种肿瘤疫苗组合物及其制备方法和应用
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
TWI522112B (zh) 疫苗佐劑、疫苗組合物與牛樟芝子實體之多醣體用於製備一疫苗佐劑的用途
Naylor et al. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines
Murphy Frontiers in cancer immunotherapy
Yang et al. Dendritic cells pulsed with GST–EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma
Behboudi et al. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
Shafer-Weaver et al. T cell tolerance to tumors and cancer immunotherapy
Elizondo et al. Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52
McKenna Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance?
Schirrmacher T cell-mediated immunotherapy of metastases: state of the art in 2005